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Take-Home Message 
Low-quality evidence suggests that both high- and low-dose colchicine decreases pain in acute gout 
flares; however, high-dose regimens are associated with more frequent adverse effects. 
Methods 
Data Sources 
In this review, the authors searched the Cochrane Central Register of Controlled Trials to April 2014, 
MEDLINE (1948 to April 2014), and EMBASE (1980 to April 2014). They reviewed the 2010 to 2013 
American College of Rheumatology and the European League against Rheumatism conference 
proceedings. In addition, clintrials.gov and the WHO trials register were searched. 
Study Selection 
The authors included all randomized controlled trials and controlled clinical trials on the benefits and 
harms of colchicine in adult patients with acute gout flares, identified by the presence of monosodium 
urate crystals in joint aspirate or patients fulfilling standard criteria. The major outcomes included 
benefits, defined as 50% or greater reduction in pain at 12, 24, 36, or 48 hours; reduction of joint 
inflammation; and total number of adverse events. 
Data Extraction and Synthesis 
Two authors independently extracted data and assessed study trial suitability for inclusion. Risk of bias 
was independently assessed by 2 authors, conforming to the recommended methods of the Cochrane 
Collaboration. Disagreements were resolved by consensus. The authors pooled results with a random-
effects model and calculated heterogeneity with I2 statistics. Treatment effect was assessed with risk 
ratios for dichotomous outcomes and mean differences for continuous data and included 95% 
confidence intervals. To combine outcomes with different scales, standardized mean differences were 
calculated. 
Results 
A total of 1,035 articles were identified with the search strategy, yet only 2 studies met the inclusion 
criteria (see table). The first study included 43 patients with acute gout, diagnosed by synovial analysis, 
and compared high-dose oral colchicine (1 mg initially followed by 0.5 mg every 2 hours until pain relief 
or adverse effects; mean total dose 6.7 mg) with placebo. Nonsteroidal anti-inflammatory medications 
were withheld from all patients for 48 hours. The second study included 575 patients with acute gout 
according to the American College of Rheumatology preliminary classification criteria who were 
randomized to one of 3 groups: high-dose oral colchicine (4.8 mg during 6 hours), low-dose oral 
colchicine (1.8 mg during 1 hour), or placebo. Nonsteroidal anti-inflammatory medications were allowed 
if patients had intolerable pain after the first dose of study drug. Patients’ pain was recorded on 
continuous scales in both studies, whereas the first study also measured inflammation and the second 
study recorded adverse events. 
Commentary 
Gout is a disease characterized by acute, severely painful attacks triggered by the deposition of 
monosodium urate crystals in joints. It is the most common cause of inflammatory arthritis in adults.1 
Multiple treatments have been used for acute gout flares, including nonsteroidal anti-inflammatory 
medications, opioids, systemic corticosteroids, intra-articular corticosteroids, and ice1, 2, 3 and 4; 
however, the evidence behind many of these treatment modalities is limited. A recent systematic review 
found only 1 low-quality trial comparing nonsteroidal anti-inflammatory medications with placebo, 
which reported an increase in the proportion of patients with at least 50% pain reduction (risk 
ratio=2.75; 95% confidence interval 1.13 to 6.72).5 
Colchicine is a medication that has been used for centuries in the treatment of inflammatory arthritis 
and acts by multiple mechanisms to suppress an acute gout flare.6 However, significant concerns have 
been raised about the frequency of serious adverse effects from colchicine, particularly gastrointestinal 
distress, hematologic effects, acute kidney injury, and even death with excessive doses.6 
The goal of this systematic review was to analyze the benefits and adverse effects of using colchicine to 
treat an acute gout flare. The authors conducted a rigorous search but were able to locate only 2 
randomized controlled trials comparing colchicine to placebo and none comparing colchicine to other 
treatment modalities. The larger of the 2 trials was judged to be at uncertain risk of bias and was 
industry sponsored.7 The other study was judged to be at low risk of bias but included only 45 patients.8 
Despite the limited data, colchicine appears to provide pain relief during acute gout flares at both high 
and low doses compared with placebo. The authors of this review calculated a number needed to treat 
of 4 for high-dose colchicine and 5 for low-dose colchicine. More important, the incidence of adverse 
effects, particularly gastrointestinal effects, was high, with a calculated number need to harm of 2 in the 
high-dose colchicine group; this low number highlights the high incidence of adverse events with 
colchicine. 
Providers should weigh the risks and benefits of colchicine compared with other treatment options, 
considering the limited evidence for those alternative treatments as well. Research indicates that high-
dose colchicine regimens are not superior, and they are not recommended by clinical guidelines. When 
colchicine is used to treat an acute gout flare, a low-dose regimen (1.2 mg followed by a single 0.6-mg 
dose 1 hour later) appears to provide a similar benefit with less potential harm. 
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Editor’s Note: This is a clinical synopsis, a regular feature of the Annals’ Systematic Review Snapshot 
(SRS) series. The source for this systematic review snapshot is: van Echteld I, Wechalekar MD, 
Schlesinger N, et al. Colchicine for acute gout. Cochrane Database Syst Rev. 2014;(8):CD006190.
Table. Results for colchicine versus placebo in acute gout treatment. 
Colchicine Outcome∗ Placebo Risk Colchicine Risk Risk Ratio (95% 
CI) 
High dose 50% or greater reduction in 
pain 
240/1<comma>000 518/1<comma>000 2.16 (1.28–
3.65) 
50% or greater reduction in 
inflammation 
48/1<comma>000 504/1<comma>000 10.50 (1.48–74.38) 3 (2–19) 
Total adverse events 220/1<comma>000 838/1<comma>000 3.81 (2.28–6.38) 2 (2–5) 
Low dose 50% or greater reduction in 
pain 
172/1<comma>000 418/1<comma>000 2.43 (1.05–
5.64) 
Total adverse events 203/1<comma>000 257/1<comma>000 1.24 (0.55–2.79) n/a† 
 
